Physician profile
Stephen C Dalm
NPI 1114028255
$47,660.59
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $1,617 · 2021: $2,456 · 2022: $6,689 · 2023: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,009.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $20,221.59 | 2021-2023 | Nexplanon |
| Abbvie INC. | $16,782.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $7,646.49 | 2019-2021 | |
| Minerva Surgical, INC | $1,081.25 | 2019-2022 | |
| Novo Nordisk INC | $360.79 | 2019-2022 | |
| Allergan, INC. | $192.85 | 2019-2021 | |
| Axonics, INC. | $115.86 | 2020-2022 | |
| Pfizer INC. | $115.18 | 2020-2022 | |
| Daiichi Sankyo INC. | $112.11 | 2019-2022 | |
| Aspira Women'S Health INC | $99.12 | 2022 | |
| Myovant Sciences INC. | $93.89 | 2021-2022 | |
| Astellas Pharma US INC | $88.86 | 2020-2021 | |
| Lupin INC. | $78.94 | 2019-2020 | |
| Therapeuticsmd, INC. | $75.12 | 2019-2021 | |
| Coopersurgical, INC. | $69.88 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $48.93 | 2021 | |
| Acessa Health INC. | $43.20 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $42.11 | 2021-2022 | |
| Hologic Sales and Service, LLC | $39.42 | 2021 | |
| Dysis Medical, INC. | $36.10 | 2020-2021 | |
| Eisai INC. | $35.64 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.08 | 2021 | |
| Becton, Dickinson and Company | $29.88 | 2021 | |
| Vertical Pharmaceuticals, LLC | $29.60 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $26.06 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $24.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.06 | 2020 | |
| Acelrx Pharmaceuticals, INC. | $22.88 | 2021 | |
| Ascend Therapeutics US, LLC | $22.09 | 2021 | |
| Olympus America INC. | $19.83 | 2019 | |
| Exeltis, USA INC. | $19.26 | 2022 | |
| Ethicon US, LLC | $15.73 | 2020 | |
| Medtronic USA, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dalm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.